Resistance mechanism to an uncompetitive inhibitor of a single-substrate, single-product enzyme: A study of Helicobacter pylori glutamate racemase

Future Medicinal Chemistry

Volumn 5, Issue 11, 2013, Pages 1203-1214

  Keating, Thomas A ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL PROTEIN; BENZODIAZEPINE DERIVATIVE; GLUTAMIC ACID; MURI PROTEIN; PEPTIDOGLYCAN; PYRAZOLOPYRIMIDINEDIONE DERIVATIVE; RACEMASE; UNCLASSIFIED DRUG;

ARTICLE; ENZYME SUBSTRATE COMPLEX; HELICOBACTER PYLORI; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE;

AMINO ACID ISOMERASES; AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BENZODIAZEPINES; BINDING SITES; CATALYTIC DOMAIN; CELL WALL; DRUG RESISTANCE, BACTERIAL; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; MURAMIDASE; MUTATION; PEPTIDOGLYCAN; PROTEIN BINDING; PYRIMIDINONES; SEQUENCE ALIGNMENT; SUBSTRATE SPECIFICITY;

EID: 84893363349     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.13.94     Document Type: Article

References (39)

1. Suerbaum S, Michetti P. Helicobacter pylori infection. N. Engl. J. Med. 347, 1175-1186 (2002).
2. Gisbert JP, Calvet X. The effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment. Pharmacol. Ther. 34, 1255-1268 (2011).
3. Uemura N, Okamoto S, Yamamoto S, et al.: Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 345, 784-789 (2001).
4. Noto JM, Peek Jr. RM. Helicobacter pylori: An overview. Methods Mol. Biol. 921, 7-10 (2012).
5. Then RL, Sahl H-G. Anti-infective strategies of the future: Is there room for species-specific antibacterial agents? Curr. Pharm. Des. 16, 555-566 (2010).
6. Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J. Gastroenterol. 17, 3971-3975 (2011).
7. Krosky DJ, Alm R, Berg M, et al.: Helicobacter pylori 3-deoxy-d-manno-octulosonate-8-phosphate (KDO-8-P) synthase is a zinc-metalloenzyme. Biochim. Biophys. Acta 1594, 297-306 (2002).
8. Lundqvist T, Fisher SL, Kern G, et al.: Exploitation of structural and regulatory diversity in glutamate racemases. Nature 447, 817-822 (2007).
9. Noonan B, Alm RA. Novel intervention strategies for Helicobacter pylori treatment. Curr. Drug Targets Infect. Disord. 2, 331-338 (2002).
10. Trust TJ, Alm RA, Pappo J. Helicobacter pylori: Today's treatment, and possible future treatment. Eur. J. Surg. Suppl. 586, 82-88 (2001).
11. Duckworth MJ, Okoli AS, Mendz GL. Novel Helicobacter pylori therapeutic targets: The unusual suspects. Expert Rev. Anti-Infect. Ther. 7, 835-867 (2009).
12. Keating TA, Newman JV, Olivier NB, et al.: In vivo validation of thymidylate kinase (TMK) with a rationally designed, selective antibacterial compound. ACS Chem. Biol. 7, 1866-1872 (2012).
13. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL. Drugs for bad bugs: Confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6, 29-40 (2007).
14. Bugg TDH, Braddick D, Dowson CG, Roper DI. Bacterial cell wall assembly: Still an attractive antibacterial target. Trends Biotechnol. 29, 167-173 (2011).
15. Van Heijenoort J. Recent advances in the formation of the bacterial peptidoglycan monomer unit. Nat. Prod. Rep. 18, 501-519 (2001).
16. Baum EZ, Montenegro DA, Licata L, et al.: Identification and characterization of new inhibitors of the Escherichia coli MurA enzyme. Antimicrob. Agents Chemother. 45, 3182-3188 (2001).
17. Silver LL. Challenges of antibacterial discovery. Clin. Microbiol. Rev. 24, 71-109 (2011).
18. Conti P, Tamborini L, Pinto A, et al.: Drug discovery targeting amino acid racemases. Chem. Rev. 111, 6919-6946 (2011).
19. Doublet P, Van Heijenoort J, Bohin J-P, Mengin-Lecreulx D. The murI gene of Escherichia coli is an essential gene that encodes a glutamate racemase activity. J. Bacteriol. 175, 2970-2979 (1993).
20. Fisher SL. Glutamate racemase as a target for drug discovery. Microb. Biotechnol. 1, 345-360 (2008).
21. Gallo KA, Tanner ME, Knowles Jr. Mechanism of the reaction catalyzed by glutamate racemase. Biochemistry 32, 3991-3997 (1993).
22. Glavas S, Tanner ME. Active site residues of glutamate racemase. Biochemistry 40, 6199-6204 (2001).
23. Mixcoha E, Garcia-Viloca M, Lluch JM, González-Lafont À. Theoretical analysis of the catalytic mechanism of Helicobacter pylori glutamate racemase. J. Phys. Chem. B 116, 12406-12414 (2012).
24. De Jonge BLM, Kutschke A, Uria-Nickelsen M, Kamp HD, Mills SD. Pyrazolopyrimidinediones are selective agents for Helicobacter pylori that suppress growth through inhibition of glutamate racemase (MurI). Antimicrob. Agents Chemother. 53, 3331-3336 (2009).
25. Geng B, Basarab G, Comita-Prevoir J, et al.: Potent and selective inhibitors of Helicobacter pylori glutamate racemase (MurI): Pyridodiazepine amines. Bioorg. Med. Chem. Lett. 19, 930-936 (2009).
26. Basarab GS, Hill P, Eyermann CJ, Gowravaram M, Käck H, Osimboni E. Design of inhibitors of Helicobacter pylori glutamate racemase as selective antibacterial agents: Incorporation of imidazoles onto a core pyrazolopyrimidinedione scaffold to improve bioavailability. Bioorg. Med. Chem. Lett. 22, 5600-5607 (2012).
27. Basarab GS, Hill PJ, Rastagar A, Webborn PJH. Design of Helicobacter pylori glutamate racemase inhibitors as selective antibacterial agents: A novel pro-drug approach to increase exposure. Bioorg. Med. Chem. Lett. 18, 4716-4722 (2008).
28. Keating TA, Fisher SL, Lundqvist T. Novel 2-methylamino-benzodiazepine inhibitors selective for Helicobacter pylori glutamate racemase (MurI). Presented at: 46th ICAAC Meeting. CA, USA, 27-30 September 2006.
29. De Jonge BLM, Kutschke A. 2-methylamino-benzodiazepines are selective agents of Helicobacter pylori by inhibiting glutamate racemase (MurI). Presented at: 46th ICAAC Meeting. CA, USA, 27-30 September 2006.
30. Whalen KL, Tussey KB, Blanke SR, Spies MA. Nature of allosteric inhibition in glutamate racemase: Discovery and characterization of a cryptic inhibitory pocket using atomistic MD simulations and pKa calculations. J. Phys. Chem. B 115, 3416-3424 (2011).
31. Hardy JA, Wells JA. Searching for new allosteric sites in enzymes. Curr. Opin. Struct. Biol. 14, 706-715 (2004).
32. Scheer JM, Romanowski MJ, Wells JA. A common allosteric site and mechanism in caspases. Proc. Natl Acad. Sci. USA 103, 7595-7600 (2006).
33. Heise CE, Murray J, Augustyn KE, et al.: Mechanistic and structural understanding of uncompetitive inhibitors of caspase-6. PLoS ONE 7(12), e50864 (2012).
34. Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB Jr, Stewart L. The mechanism of topoisomerase I poisoning by a camptothecin analog. Proc. Natl Acad. Sci. USA 99, 15387-15392 (2002).
35. VanScyoc WS, Holdgate GA, Sullivan JE, Ward WHJ. Enzyme kinetics and binding studies on inhibitors of MEK protein kinase. Biochemistry 47, 5017-5027 (2008).
36. Singh A, Hodgson N, Yan M, et al.: Screening Helicobacter pylori genes induced during infection of mouse stomachs. World J. Gastroenterol. 18, 4323-4334 (2012).
37. Parikh SL, Xiao G, Tonge PJ. Inhibition of InhA, the enoyl reductase from Mycobacterium tuberculosis, by triclosan and isoniazid. Biochemistry 39, 7645-7650 (2000).
38. Basso LA, Zheng R, Musser JM, Jacobs WR Jr, Blanchard JS. Mechanisms of isoniazid resistance in Mycobacterium tuberculosis: Enzymatic characterization of enoyl reductase mutants identified in isoniazid-resistant clinical isolates. J. Infect. Dis. 178, 769-775 (1998).
39. Copeland RA. Conformational adaptation in drug-Target interactions and residence time. Future Med. Chem. 3, 1491-1501 (2011).